There are currently no clearly defined parameters available for therapy management, as the updated S3 guideline on the diagnosis and treatment of Crohn’s disease published last year states. This is a dilemma that raises the question of other indicators for evaluating the course of treatment. In the PROFILE study, a treatment strategy involving the early use of a biologic proved to be superior to the standard procedure in terms of steroid-free and surgery-free remission.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Atherosclerotic Coronary Plaques in High-Risk Patients
Who benefits from preventive PCI?
- Colorectal Cancer
Insulin Resistance, Obesity, and Progression
- Modern asthma therapies
New data on biologics and triple therapy
- From symptom to diagnosis
Abdominal Pain – Focal Nodular Hyperplasia
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Hepatology and Metabolism
The Mediterranean Diet for MASLD/MASH—What the EASL-EASD-EASO Guidelines Specifically Recommend
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?
Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs
- PMR and LVV: Current EULAR Recommendations